SCHEMBL17192035

SCHEMBL17192035

COc1ccc(COc2cc3c(c(Cl)c2OCc2ccc(OC)cc2)c(=O)n(CCCl)c(=O)n3C)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.38
MAOA P21397 1/20 0.38
UBE2N P61088 1/20 0.37
POLB P06746 3/20 0.37
TRPC5 Q9UL62 2/20 0.36
GRM2 Q14416 1/20 0.35
PARG Q86W56 1/20 0.35
NPBWR1 P48145 1/20 0.35
KDM4E B2RXH2 3/20 0.35
LMNA P02545 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
ALDH1A1 P00352 1/20 0.35
PLK1 P53350 1/20 0.35
PIK3CD O00329 1/20 0.35
MEN1 O00255 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17192037 0.88 KCNH2 (0.44) KDM4EALDH1A1MEN1GAAKMT2A
SCHEMBL15680550 0.87 PARG (0.35) MAOBMAOAUBE2NPOLBTRPC5
SCHEMBL17192036 0.79 S100B (0.38) UBE2NTRPC5GAAKMT2A
SCHEMBL17181483 0.76 TNF (0.47) POLBNPBWR1KDM4EPLK1
SCHEMBL17181536 0.73 TNF (0.51) POLBNPBWR1KDM4EALDH1A1PLK1
SCHEMBL15670882 0.73 SYK (0.42) POLBNPBWR1KDM4ELMNACYP1A2
SCHEMBL17181557 0.73 TP53 (0.40) POLBKDM4ELMNACYP1A2CYP3A4
SCHEMBL17192038 0.72 KDM4E (0.43) MAOBMAOAPOLBKDM4ELMNA
SCHEMBL17181465 0.72 CHRM1 (0.44) POLBKDM4ELMNACYP1A2CYP3A4
SCHEMBL14854382 0.71 ALDH1A1 (0.38) POLBKDM4ELMNACYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10174053-B2 2 substituted cephem compounds GLAXO GROUP LIMITED (GB) 2019-01-08 US disclosed
US-20170281532-A1 2 SUBSTITUTED CEPHEM COMPOUNDS GLAXO GROUP LIMITED (GB) 2017-10-05 US disclosed
US-20170281532-A1 2 SUBSTITUTED CEPHEM COMPOUNDS GLAXO GROUP LIMITED (GB) 2017-10-05 US disclosed
US-20150299223-A1 2-SUBSTITUTED CEPHEM COMPOUNDS GLAXO GROUP LTD (GB) 2015-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170281532-A1 2 SUBSTITUTED CEPHEM COMPOUNDS CEP170, CES2, CMBL MAOB 931/4885MAOA 891/4885UBE2N 47/4885
US-20150299223-A1 2-SUBSTITUTED CEPHEM COMPOUNDS CEP170, ABL1, CEPT1 MAOB 1864/4885MAOA 2146/4885UBE2N 486/4885
US-10174053-B2 2 substituted cephem compounds CEP170, CES2, CMBL MAOB 931/4885MAOA 891/4885UBE2N 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.